Frequency Therapeutics up on completing enrollment in hearing loss therapy trial

Korro Bio

12/10/2022 16:00

** Shares of drug developer Frequency Therapeutics Inc
 FREQ.O  rise as much as 9.5% to $1.90 in morning trade
    ** Co completes patient enrollment in mid-stage trial
testing FX-322 for treating sensorineural hearing loss (SNHL)
 urn:newsml:reuters.com:*:nBw8xFC04a
    ** SNHL is a type of hearing loss caused by damaged hair
cells in the inner ear
    ** The study, which enrolled 142 individuals, is designed to
evaluate the efficacy of FX-322 on speech perception in patients
aged 18-65 with hearing loss 
    ** FX-322 is designed to repair the underlying cause of SNHL
and improve overall sound clarity in patients
    ** FREQ earlier aligned with the U.S. Food and Drug
Administration on the use of the specific speech perception as
primary goal of the study 
    ** Co plans to release study data in Q1 2023
    ** Including session moves, stock down 66.2% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))